Purpose Long-acting bronchodilator (LABD) use is the mainstay of pharmacologic treatment
for chronic obstructive pulmonary disease (COPD). Few studies describe evolving patterns …

Background and objective While several studies have found that prescribing practices do
not conform to chronic obstructive pulmonary disease (COPD) treatment guidelines, none …

Introduction This study aimed to characterize patients with chronic obstructive pulmonary
disease (COPD) newly prescribed a long-acting bronchodilator (LABD), and to assess …

Introduction There is limited real-world evidence regarding clinical practice for chronic
obstructive pulmonary disease (COPD) in Singapore. We compared baseline clinical …

Background To assess the symptomatic and cost burden among patients initiating long-
acting bronchodilator (LABD) therapy and impact of adherence on healthcare resource use …

Background This study characterized a cohort of chronic obstructive pulmonary disease
(COPD) patients on maintenance bronchodilator monotherapy for≥ 6 months to establish …

Abstract The Global Initiative for Chronic Obstructive Lung Disease (GOLD)
recommendations for the initial bronchodilator to use in newly diagnosed chronic obstructive …

Objective Management of chronic obstructive pulmonary disease (COPD) with inhaled
corticosteroid/long-acting β2-agonist (ICS/LABA) improves lung function and health status …

Background: Single-inhaler LAMA/LABA is recommended by the Global Initiative for Chronic
Obstructive Lung Disease (GOLD) as maintenance therapy for patients with COPD, but the …

Purpose Clinical guidelines for COPD management suggest pharmacologic treatment
algorithms based on symptoms and exacerbation history. As previous research has …